KIT and melanoma: In melanoma cell lines that have not been selected for c-Kit mutations, dasatinib decreases cellular proliferation (Eustace et al, 2010) and enhances apoptosis (Niu et al, 2002), and dasatinib decreases cell migration even in cells in which it has no antiproliferative effect (Eustace et al, 2008, 2010).